Pular para o conteúdo
Merck
  • Decreased parathyroid Klotho expression is associated with persistent hyperparathyroidism after kidney transplantation.

Decreased parathyroid Klotho expression is associated with persistent hyperparathyroidism after kidney transplantation.

Transplantation proceedings (2013-10-26)
Y A Hong, D E Choi, S W Lim, C W Yang, Y-K Chang
RESUMO

Although successful kidney transplantation usually corrects hyperparathyroidism, the condition persists in some patients. The present study was designed to determine whether Klotho or fibroblast growth factor 23, the key regulator of parathyroid hormone, is involved in persistent hyperparathyroidism in kidney transplant recipients (KTRs). Nineteen hyperplastic parathyroid glands were obtained from end-stage renal disease (ESRD) patients and KTRs; 6 normal parathyroid glands were used as controls. We compared the expression of Klotho, fibroblast growth factor receptor 1 (FGFR1) and calcium-sensing receptor (CaSR) in the KTRs and ESRD patients. Expressions of Klotho, FGFR1, CaSR and vitamin D receptor, as evaluated by immunohistochemistry, were quantified as the number of positive cells per unit area. The Klotho, FGFR1 and CaSR expressions in parathyroid glands of the post-kidney transplantation (PSKT) and the ESRD groups were significantly decreased compared with normal controls. In the ESRD group, Klotho expression and number of proliferating cell nuclear antigen-positive cells in the parathyroid gland were significantly decreased in parathyroid adenomas as compared with parathyroid hyperplasia. The expression of FGFR1 and CaSR in the parathyroid glands was significantly increased in the PSKT compared with the ESRD group. There was no significant difference in Klotho expression between the PSKT and ESRD groups. Incomplete recovery of Klotho levels in the parathyroid gland may play a role in the pathogenesis of tertiary hyperparathyroidism after kidney transplantation.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
β-Glicuronidase, Type HP-2, aqueous solution, ≥100,000 units/mL
Sigma-Aldrich
β-Glicuronidase, Type H-2, aqueous solution, ≥85,000 units/mL
Sigma-Aldrich
β-Glicuronidase, Type H-1, partially purified powder, ≥300,000 units/g solid
Sigma-Aldrich
βß-Glicuronidase, Type IX-A, lyophilized powder, 1,000,000-5,000,000 units/g protein (30 min assay)
Sigma-Aldrich
β-Glicuronidase, Type H-5, lyophilized powder, ≥400,000 units/g solid
Sigma-Aldrich
βß-Glicuronidase, Type L-II, lyophilized powder, 1,000,000-3,000,000 units/g solid
Sigma-Aldrich
β-Glicuronidase, Type HP-2S, aqueous solution, ≥90,000 units/mL
Sigma-Aldrich
βß-Glicuronidase, Type VII-A, lyophilized powder, 5,000,000-20,000,000 units/g protein, pH 6.8 (30 min assay)
Sigma-Aldrich
β-Glucuronidase from bovine liver, Type B-1, ≥1,000,000 units/g solid
Sigma-Aldrich
β-Glicuronidase, Type H-3, aqueous solution, ≥90,000 units/mL
Sigma-Aldrich
βß-Glicuronidase, >20,000,000 units/g protein, recombinant, expressed in E. coli, aqueous glycerol solution
Sigma-Aldrich
βß-Glicuronidase, ≥20,000 units/mg protein, recombinant, expressed in E. coli overproducing strain, lyophilized powder
Sigma-Aldrich
βß-Glicuronidase, ≥10,000,000 units/g protein (30 min assay), recombinant, expressed in E. coli overproducing strain, lyophilized powder
Sigma-Aldrich
βß-Glicuronidase, aqueous glycerol solution, ≥5,000,000 units/g protein, pH 6.8 (biuret)
Sigma-Aldrich
βß-Glicuronidase, aqueous solution, ≥85,000 units/mL
Sigma-Aldrich
β-Glucuronidase from bovine liver, Type B-3, ≥2,000,000 units/g solid
Sigma-Aldrich
β-Glicuronidase, Type H-3AF, aqueous solution, ≥60,000 units/mL
Sigma-Aldrich
β-Glucuronidase from Helix aspersa (garden snail), Type HA-4